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Adenoviral-medlated gene transfer to renal tubular cells in vivo. The
efficient introduction of genetic material into quiescent renal cells is
potentially important in the study of renal physiopathology and for gene
therapy of kidney related disorders. A replication-deficient adenoviral
vector that contained a reporter gene encoding the nuclear J3-galacto-
sidase was either selectively perfused into the renal artery or infused
through a retrograde catheter into the pyelic cavity of the left kidney of
adult rats. Highly efficient gene transfer was achieved by either route of
administration, and nuclear J3-galactosidase activity was detected for
two to four weeks following a progressive decline of expression.
Genetically-modified cells were identified as proximal tubular cells
when the adenoviral vector was selectively perfused via the renal
artery, while tubular cells from the papilla and medulla were selectively
transduced by retrograde infusion of the viral vector. No obvious
cytopathic effect was observed. We conclude that: (i) efficient gene
transfer in renal tubular cells can be achieved by adenoviral vectors; (ii)
the targeted cell population can be chosen through the route of
administration.
The ability to deliver foreign gene and promoter elements into
mammalian kidney would make it feasible to introduce biolog-
ically active peptide molecules into the kidney for therapeutic
purposes or to address specific issues in experimental nephrol-
ogy. For in vivo gene transfer, most attention has been focused
on the use of viral vectors such as recombinant retroviruses or
adenoviruses [reviewed in [1], although nonviral vectors where
the DNA is either naked or electrostatically complexed with
inert substrates have recently demonstrated some potential [2,
3]. Recombinant retroviruses are currently the most widely
used vectors for the introduction of genes into a broad variety
of mammalian cells. However, the expression of the foreign
gene needs its integration into the host genome which is
dependent upon division of the targeted cell at the time of viral
infection [4]. This precludes gene transduction in the kidney in
which one is dealing with differentiated postmitotic cells. Al-
though in a recent study [5] it was possible to induce, in adult
rats, acute tubular cell replication after folic acid treatment, the
direct injection into the kidney parenchyma, at this stage, of
recombinant retroviruses carrying the 13-galactosidase reporter
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gene resulted in only 0.5 to 1% transduction efficiency within
the injected area.
An alternative approach for in vivo gene transfer into the
kidney is the use of recombinant adenoviruses which have
important advantages including: (i) they can be grown to
extremely high titers; (ii) transfer and expression of the recom-
binant gene can be accomplished in non-dividing cells; (iii) they
present a wide cell type tropism; and (iv) they can interact with
various basement membranes. The general strategy is to pro-
duce recombinant adenovirus that are replication defective by
virtue of deletions of Ela and Elb sequences.
To assess the suitability of recombinant adenoviral vectors
for in vivo renal gene transfer, we used an El deleted adenovi-
rus carrying the f3-galactosidase reporter gene [6] either selec-
tively perfused into the left renal artery or applied by retrograde
infusion into the left ureter of adult rats. Controlateral kidneys
(right kidneys) were used as internal controls. We looked, at
one to four weeks after gene delivery, for the presence of
nuclear /3-galactosidase-expressing renal cells as well as for the
possible renal cytotoxic effects of the recombinant adenoviral
vector.
Methods
Experimental strategy
A recombinant adenovirus which transduces, under the con-
trol of a Rous sarcoma virus (RSV) promoter, the lacZ gene
(nlslacZ), coding for the Escherichia coli /3-galactosidase, was
used as vector (Ad-f3gal). The lacZ gene was fused to a
21-amino acid nuclear localization sequence from simian virus
40 large tumor antigen which resulted in the specific and
exclusive nuclear localization of the protein [7]. To test whether
the adenovirus construct is able to direct /3-galactosidase ex-
pression in kidney, we selectively perfused the viral preparation
into the left renal artery or ureter of 8- to 10-week-old Wistar
rats (Iffa Credo, l'Arbresle, France). Animals were sacrificed at
different time intervals from 7 to 30 days after the selective
artery perfusions or ureteral infusions and genetically-modified
cells were sought by enzyme histochemistry for nuclear E. coli
f3-galactosidase. The right kidneys which have been excluded
from the recombinant Ad-gal perfusion were used as internal
controls. In addition, liver, lungs and bladder were monitored
for possible spreading of the recombinant Ad-gal out of the
perfused kidney. Urine samples from one experimental rat were
collected before surgery and at different time intervals after
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Ad-j3gal retrograde infusion to evaluate for the presence of
recombinant adenovirus.
Preparation of recombinant adenovirus
A replication defective adenovirus based on Ad5 serotype
was used in this study. The structure of Ad-pgal has been
described previously [6]. In this virus, El sequences from 1.3 to
9.4 have been deleted and replaced with a minigene contain-
ing the Rous sarcoma virus long terminal repeat (RSV LTR),
the lacZ gene with a nuclear localization sequence, and the
SV4O early region polyadenylation signal; in addition E3 se-
quences spanning to 78.5 to 84.7 s have been deleted.
Stocks of recombinant viruses were prepared as follows.
Cultures of L293 cells (4 x 600 cm2 plates-NUNC, Roskilde,
Denmark) grown in DMEM containing 10% fetal calf serum
(FCS), 100 U/nil penicfflin, and 100 tg/ml streptomycin were
infected at 80% confluency with a multiplicity of infection
(MOl) equal to 5 pfu per cell. Thirty hours following infection,
cells were harvested. Pellets were resuspended in 10 ml of
culture medium and subjected to four rounds of freeze-thaw,
followed by separation of cell debris by centrifugation at 4,500
rpm for five minutes. Crude viral supernatants were layered
onto a CsCl step gradient and centrifuged for one hour at 35,000
rpm. The intact viral particles were subjected to a second round
of CsCI banding for 18 hours at 35,000 rpm. Viral particles were
collected and extensively dialyzed against PBS containing 10%
glycerol. Viral stocks were titered by infecting L293 cells with
serial dilutions of the viral preparation for one hour at 37°C.
Twenty-four hours later, cells were fixed in PBS containing 1%
formaldehyde and 0.5% glutaraldehyde and stained with X-Gal
(see Cytochemical Analysis) for 18 hours at 30°C. The number
of blue clones was evaluated to determine the viral titer. Viral
stocks were frozen at —80°C in 10% glycerol until they were
used. Immediately prior their use, viral stocks were diluted in
PBS to 1 to 5 x 1010 pfu/ml. None of the stocks of virus used in
the experiments contained detectable replication-competent
viruses as evaluated on HeLa cells after extended cultivation
[6].
Asanguineous surgical perfusion of the kidney
The left kidney of seven adult rats was exposed and its blood
flow was interrupted for less than 10 minutes by clamping the
aorta under the superior mesentenc artery and above the
inferior mesenteric artery. This setting selectively excluded the
left kidney without interrupting the blood flow through the
controlateral right kidney. Depending on its implantation, the
left adrenal artery was eventually ligated during this operation.
Using a 30 gauge needle, 1 x 1010 pfu/ml of recombinant
Ad-f3gal, suspended in PBS in a final volume of 2 ml, was
directly infused in the aorta nearby the left renal artery with a
flow rate of 1 to 2 mI/mm. Recirculation of the infused Ad-f3gal
was occasionally seen in the renal vein. After the recombinant
Ad-/3gal had been administered, renal blood flow was re-
established and the kidney was checked for its homogeneous
reperfusion.
Retrograde infusion
A PE 10 tubing (Beckton-Dickinson, Illinois, USA) was
inserted into the left ureter of 7 adult rats and slided up into the
pyelic cavity in which 300 1.d of a 5 x lO'° pfu/ml recombinant
Ad-pgal solution were infused and incubated for five minutes.
Pressure during the infusion procedure was not precisely re-
corded, however, it was done slowly without pyclic distention
and subsequent hematuria. The catheter was then removed and
urine flow was re-established. The controlateral right kidney
was selectively infused with the vehicule solution and subse-
quently used as an internal control for X-Gal staining.
Cytochemical analysis
Gene transfer was monitored on cryostat sections as de-
scribed [8]. The left and right kidneys were fixed in situ by
perfusing a 4% paraformaldehyde-PBS solution. Mter removal,
the kidneys were cut into 5 mm thick blocks. Blocks were either
incubated overnight at 30°C with 5-bromo-4-chloro-3-indolyl
j3-D-galactopyranoside (X-Gal; Sigma) substrate, pH 8.5 or
immersed overnight in PBS with 30% sucrose at 4°C, frozen in
isopentane, and used to prepare 10 jsm thick cryostat sections.
The tissue sections were then incubated with X-Gal substrate
and subsequently counterstained with hematoxylin. Samples
from lungs, liver and bladder fixed in 4% paraformaldehyde
were monitored identically for the presence of nuclear-/3-galac-
tosidase-expressing cells.
Immunocytochemical colocalization of nuclear /3-galactosi-
dase and the gp-90 brush border antigen specific for the proxi-
mal tubular cells [9] was performed as follows. After X-Gal
staining of the cryostat sections, a mouse anti-gp9O monoclonal
antibody was incubated at a dilution of 1:1000 in PBS-5% low
fat milk on kidney sections previously incubated with 3% final
H202 to inactivate the endogenous peroxidase activity. A
1:1000 diluted rabbit anti-mouse antibody (Amersham) coupled
to peroxidase was used for staining using 0.001% DAB (Amer-
sham) and cobalt chloride at 0.03% final concentration. For
routine histology, the tissues were fixed in 10% formaldehyde
prior to sectioning and staining.
Recovery of adenovirus from urine samples
To assess the ability of transduced kidneys to express recom-
binant adenovirus, urines samples were collected at timed
intervals following the left ureter infusion of Rat #11 (Table 1).
All fractions were immediately evaluated for the presence of
recombinant virus on L293 cells. Cells were assayed for nuclear
f3-galactosidase activity by X-Gal staining and results expressed
as number of positive cells per ml and mg of creatininuria.
Creatinine was measured as described [10].
Results
Renal artery perfusion
No macroscopic change was found immediately after the
Ad-pgal perfusion and at the time of sacrifices (7, 15, and 30
days). Kidneys appeared homogeneously perfused and not
different from the controlateral untransduced kidneys. Routine
histology indicated that left kidneys structures were conserved
and undistinguishable from the controlateral kidneys at 7, 15
and 30 days after the transduction procedure (data not shown).
Nuclear J3-galactosidase activity could be readily detected on
kidney blocks for up to 15 days after recombinant Ad-/3gal
perfusion, exclusively limited to the cortex in an heterogenous
fashion (Fig. 1A). Table 1 shows an estimation of the positive
cells within the cortex area, scored on X-Gal-stained cryostat
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Table 1. Nuclear 13-galactosidase expression in transduced left
kidneys
Nuclear 13-galactosidase
Renal artery Day of
expressiona
Medulla!
perfusion sacrifice Cortex papilla
Rat#l 7 ++ 0
#2 7 0
#3 15 ++-f- 0
#4 15 ++ 0
#5 15 ++ 0
#6 30 + 0
#7 30 0 0
Ureteral retrograde
infusion
Rat#8 7 0 +
#9 7 0
#10 7 0 ++
#11 10 + ++
#12 15 0 +
#13 15 0 0
#14 15 0 0
Symbols are: 0 = none; + = low; ++ = intermediate; +++ = high.
a Approximate level of tubular cell transduction
sections of experimental kidneys. A high fraction (+ + +) of
genetically-modified cells in the cortex was found in rats #2 and
#3 (Fig. 2) and an intermediate level (++) in rats #1, #4 and
#5, all sacrificed at 7or 15 days after gene delivery. In contrast,
only few scattered cells were found to be transduced in rats #6
and #7 sacrificed one month after adenoviral perfusion. 3-ga-
lactosidase-positive cells appeared exclusively located in the
cortex involving the tubular cells with no evidence of any gene
transfer in glomerular structures as well as vascular or intertitial
compartments (Fig. 2). The controlateral kidney never con-
tained j3-galactosidase-positive cells (Figs. lb and 4). Counter-
staining the kidney sections with a monoclonal antibody recog-
nizing gp 90, a specific antigen on the proximal tubular brush
border [9], disclosed that j3-galactosidase-positive cells were
exclusively proximal tubular cells (Fig. 3).
Since the Ad-/3gal can infect a number of different cell types
and the delivery system used here does not preclude the
infection of other tissues, we evaluated whether other distant
organs were transduced by this gene delivery procedure. Liver
and lungs from animals #3 and #4 were examined for the
expression of /3-galactosidase-positive cells by X-Gal staining.
None could be detected (data not shown), suggesting that the
first passage through the kidney via the renal artery route
resulted in the vast majority of the virus being taken up by the
proximal tubular cells.
Retrograde infusion
Since ureteral retrograde catheterization is a common clinical
procedure, we were willing to document the possibility of
transferring foreign gene in situ into kidney cells via this simple
and highly selective route. Among the seven rats that we have
infused and further investigated at different time intervals (7, 10
and 15 days), macroscopic view and routine histology did not
show any evidence of hemodynamic and cytotoxic effects
related to the use of the adenoviral vector via this retrograde
procedure. Renal structures remained unchanged even soon
after the retrograde infusion of Ad-f3gal (7 days) and no signif-
icant difference was noted when compared to the internal
controls represented by the controlateral kidneys infused with
the vehicule buffer only. Nuclear /3-galactosidase activity could
be easily detected on kidney blocks seven days after recombi-
nant Ad-f3gal perfusion (data not shown), exclusively limited to
the papillas with an extremely high intensity in some areas for
rat #9. Table 1 shows an estimation of the positive cells within
the papillary/medullary regions, scored on sections of experi-
mental kidneys. A high (+ + +) fraction of transduced cells was
found in rat #9, sacrificed seven days after Ad-/3gal infusion
(Fig. 5). Rats #10 and #11 exhibited an intermediate (+ +) level
of genetically modified cells within the papilla and medulla
areas when examined 7 and 10 days after retrograde infusion. In
contrast, only few (+) cells were found to be transduced in rats
#8 and #12 sacrificed at 7 and 15 days, respectively. Finally,
two animals (rats #13 and #14) were found negative on several
cryostat sections screened.
Despite heterogeneity in gene transfer efficiency in this
group, individualized analysis revealed that the /3-galactosi-
dase-expressing cells appeared essentially limited to the me-
dulla and papilla, involving the tubular cells with no evidence of
any gene transfer into glomerular structures as well as the
interstitial compartment (Figs. S and 6).
After gene delivery, urine was evaluated for the presence of
recombinant Ad-/3gal using L293 cells. In rat #11, which
exhibited transduced medulla and papilla (Table 1) with no
detectable /3-galactosidase-positive cells on bladder sections,
the concentration of virus in the urine samples dropped precip-
itously during the first two days following the retrograde gene
transfer procedure (3750 pfu/ml!hr mg1 creatininuria at day
1, 240 pfu/ml/hr mgt creatininuria at day 2) and stabilized
within barely detectable levels (<10 pfu/ml).
Discussion
We show that recombinant adenovirus vector can efficiently
transduce kidney cells upon selective perfusion of the renal
artery or retrograde infusion via the ureter without detectable
tissue injury. The present work illustrates that the kidney is a
target for gene transfer to be added to the increasing list of
permissive organs to recombinant adenoviruses [reviewed in 1,
11]. Efficient expression was observed in short-term experi-
ments (up to 15 days) with intense staining of the /3-galactosi-
dase reporter gene in either the cortex or medulla depending on
the route of administration. Using the renal artery perfusion
route, gene transfer occurred exclusively in proximal tubular
cells as evidenced by colocalization of nuclear /3-galactosidase
Figs. 1—6. Histochemical staining of kidneys from rat #3 (Figs. Ia, lb, 2, 3 and 4) and rat #9 (Figs. Sand 6). X-Gal staining of 5 mm thick blocks
from the left experimental kidney la) and from the right control kidney (Fig. lb) examined with a binocular microscope (7.5x). Cryostat sections
of the Ad-f3gal-perfused left kidney stained with X-Gal and either counterstained with hematoxylin (Fig. 2, 75 x) or incubated with a monoclonal
antibody against a proximal brush border antigen, gp9O, revealed by an anti-mouse IgG antibody peroxidase-labeled (Fig. 3, 140X). Arrows indicate
the nuclear 13-galactosidase. X-gal staining and anti gp9O labelling on the control right kidney (Fig. 4, l4OX). Distribution of the genetically-modified
tubular cells in the papilla of rat #9 (Figs. 5, x25 and 6, 250x).
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activity with gp9O-positive brush borders throughout the cor-
tex. No 3-galactosidase transduced cells could be detected in
glomeruli, interstitium as well as in the medulla and papilla.
Conversely, using the retrograde route through the ureter led to
highly efficient gene transfer strictly targeted to medullar and
papillar epithelial cells, possibly collecting tubular cells, at least
in part. However, it has to be emphasized that in both routes of
administration gene transfer occurred with a striking heteroge-
neity. For instance, as seen Figure 5, the p-galactosidase-
positive papilla is so intense that diffusion of X-Gal precipitates
made the quantification of cell types within large, highly ex-
pressing clusters difficult as the remaining papilla in the vicinity
is almost devoid of transduced-positive cells. Similarly, at the
cortex level, when using the renal artery perfusion route, areas
with a high density of /3-galactosidase-positive cells alternate
with areas with negative to low density of transduced proximal
tubular cells (Fig. 2). This high heterogeneity may be related to:
(i) the low perfusion rate; (ii) the particular renal artery network
throughout the cortex; (iii) a dilution factor increasing as the
adenoviral perfusate floods the kidney; and (iv) the lack of a
mixing chamber upstream of the kidney. Whatever explanation
prevails, such heterogeneity renders precise quantification im-
possible and requires optimization and standardization of the
gene transfer procedures.
Despite these pitfalls, the recombinant adenovirus vector
appeared more efficient than that observed in experiments
carried out by direct injection into the renal cortex of a
retroviral vector suspension carrying the /3-galactosidase re-
porter gene [5]. In these experiments, less than 1% of tubules-
containing positive cells were found exclusively within the
injection site. Although this latter study suggested that expres-
sion of the transferred reporter gene could be detected at least
seven weeks, it required the induction of an acute nephrotoxic
injury prior the use of the retroviral vector. Conversely, using
Ad-f3gal vector did not required any invasive procedure nor had
any cytotoxic effect at the viral titer used (1 x 1010 pfulml).
However, the number of genetically-modified tubular cells
appeared to decrease over time. Despite the unconveniency to
follow individual animals over time using an intracellular
marker such as /3-galactosidase, the reproducibility of transduc-
tion efficiency allowed the evaluation of individual animals at
different time points after gene delivery even though ureteral
retrograde infusion appeared more difficult to control. At day
15, using the retrograde infusion, only few (+) /3-galactosidase-
expressing tubular cells were found within the medulla and
papilla as compared to intermediate (+ +) or high (+ + +) levels
of transduction one week after gene transfer. By 30 days after
selective perfusion of the renal artery, only rare (+) transduced
proximal tubular cells were detected in individual animals as
intermediate (+ +) to high (+ + +) levels of transduction were
found two weeks after gene delivery. This progressive decrease
may be related to: (i) experimental variations between experi-
mental kidneys; (ii) inactivation at the host cell level of the RSV
LTR promoter used in the Ad-/3gal construct as already docu-
mented in vivo with other viral promoters in fibroblasts [12],
[13]; (iii) since adenoviral genome does not integrate into the
host genome [14], the DNA may be gradually lost from tubular
cells over time related to the low rate cell replication found in
healthy adult mammalian kidney [15]. Indeed, in vivo persis-
tency of episomal expression from adenoviral vectors is more-
likely correlated to the turnover of the targeted cell. For
instance, sustained expression of foreign gene in muscle [16],
neurons, glia [17] have been reported for several months
whereas rapid decrease of the transgene expression (within few
weeks) was observed in transduced liver [18] and lungs [19]. It
is unlikely that transduced renal cells are selectively killed in
vivo because with a high transduction efficiency by either route
in short-term experiments, there should be evidence of tubular
regeneration in transduced animals, which was not seen on
histopathologic sections. However, these important issues will
need to be addressed experimentally.
Refinement of in vivo strategies using higher titers, larger
volumes of adenoviral solution, various timing of viral chal-
lenges could further significantly enhance gene transfer effi-
ciency. For instance, using higher adenoviral titers would
certainly represent a potential benefit in this model for two
reasons: (i) recent studies have shown that gene transfer
efficiency in vitro as well as in vivo, in liver [18], lung [20], and
muscle cells [16] is directly correlated to the titre of the
recombinant adenovirus vector within a range of 1 x iO to 1 x
1012 pfu/ml; (ii) tubular basement membrane may act on one
hand as an anatomical barrier requiring higher concentrations of
adenoviral vector, on the other hand as a relative protection
against recombinant adenovirus-induced cytopathic effect such
as described in the liver when directly challenged to titers over
7 x 1010 pfulml [18], or 1 x l0 pfu/ml in the brain [21].
The selective perfusion of the renal artery and the retrograde
ureter infusion methods that led to quantitative transduction of
tubular cells did not show detectable adenoviral leakage out of
the kidney to other tissues such as the liver, lung and bladder.
This suggest that either the virus is highly nephrotropic by these
routes of delivery and/or that titers of approximately 1 x iO'°
pfu/ml used in the present work for all experimental animals
may not represent enough viral particles to saturate renal
receptors. Whatever explanation prevails, it is worth noting
that basement membranes do not preclude infection by the
recombinant adenovirus of tubular epithelial cells via the vas-
cular route.
The persistence of recombinant adenovirus in urine samples
of rat #11, even at extremely low titer (<10 pfu/ml), 10 days
after retrograde gene delivery was unexpected. It is unlikely
that rat tubular cells are supporting low levels of virus produc-
tion because rat cells are not expected to trans-complement
replication-defective adenoviruses. It is more likely that the
virus recovered in the urine samples represents residual viruses
from the initial retrograde infusion. Such residual viral activity
was also recently reported by Engelhardt et al [20] in effluents
of human bronchial xenograft infused with a similar vector,
although in this latter case, complementation by the human
cells could be an additional explanation.
Despite that nuclear f3-galactosidase expression decreases
over time in the experimental conditions described in the
present work, the kidney represents an attractive target for
gene transfer for several reasons: (i) one of the two kidneys can
be genetically-modified selectively; (ii) depending on the route
of administration, one can address specific questions related to
the target cell or area involved; (iii) the adenovirus vector could
be a useful experimental tool to change or add the expression of
genes acutely in the kidney through simple non invasive proce-
dures on a large variety of laboratory animals; (iv) if the
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secretion of the transgene product is expected at the basolateral
side of the tubular cells, the kidney may represent an ectopic
source of a therapeutic peptide directly available in the circu-
lation [22].
Finally, the possibility of repetitive gene delivery for ex-
tended effects, the use of alternative promoters and the expres-
sion of therapeutic gene should be investigated.
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